Shares of Genomic Health, Inc. (NASDAQ:GHDX) have been assigned an average rating of “Hold” from the fourteen analysts that are currently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation, one has issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $45.25.
A number of analysts have recently issued reports on GHDX shares. Zacks Investment Research downgraded Genomic Health from a “buy” rating to a “hold” rating in a research report on Wednesday, September 5th. Raymond James started coverage on Genomic Health in a research report on Tuesday, October 23rd. They set a “market perform” rating for the company. BidaskClub upgraded Genomic Health from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, October 30th. Canaccord Genuity reiterated a “buy” rating and set a $82.00 price target (up previously from $70.00) on shares of Genomic Health in a research report on Wednesday, November 7th. Finally, Jefferies Financial Group reissued a “hold” rating and set a $50.00 price objective on shares of Genomic Health in a report on Friday, August 3rd.
Shares of GHDX traded up $0.46 during trading hours on Monday, reaching $74.22. 308,600 shares of the company’s stock traded hands, compared to its average volume of 285,380. The company has a market cap of $2.66 billion, a PE ratio of 7,422.00 and a beta of 0.44. Genomic Health has a 12 month low of $26.54 and a 12 month high of $92.18.
Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings results on Tuesday, November 6th. The medical research company reported $0.35 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.07 by $0.28. The firm had revenue of $101.30 million during the quarter, compared to the consensus estimate of $94.27 million. Genomic Health had a return on equity of 14.05% and a net margin of 4.95%. The company’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same quarter last year, the company posted ($0.06) EPS. On average, equities research analysts expect that Genomic Health will post 1.06 EPS for the current year.
In related news, CEO Kimberly J. Popovits sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, October 16th. The stock was sold at an average price of $66.26, for a total transaction of $1,656,500.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Bros. Advisors Lp Baker sold 204,300 shares of the firm’s stock in a transaction dated Tuesday, November 13th. The shares were sold at an average price of $79.33, for a total value of $16,207,119.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 696,365 shares of company stock worth $53,880,269. 45.80% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Globeflex Capital L P purchased a new position in shares of Genomic Health during the 2nd quarter valued at about $116,000. Sun Life Financial INC purchased a new position in Genomic Health in the 2nd quarter worth approximately $122,000. SG Americas Securities LLC purchased a new position in Genomic Health in the 2nd quarter worth approximately $162,000. Pacer Advisors Inc. purchased a new position in Genomic Health in the 3rd quarter worth approximately $171,000. Finally, Trexquant Investment LP purchased a new position in Genomic Health in the 3rd quarter worth approximately $202,000. 94.03% of the stock is currently owned by institutional investors.
Genomic Health Company Profile
Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.
See Also: Leveraged Buyout (LBO) Explained
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.